Morepen Laboratories Limited
NSE: MOREPENLAB BSE: MOREPENLAB
Prev Close
59.69
Open Price
58.65
Volume
1,497,181
Today Low / High
57.39 / 59.21
52 WK Low / High
42 / 100.9
Range
56 - 61
Prev Close
59.67
Open Price
58.57
Volume
109,511
Today Low / High
57.3 / 59.2
52 WK Low / High
41.66 / 100.8
Range
56 - 61
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 58.45 (target range: 56 - 61), reflecting a change of -1.24 (-2.0774%). On the BSE, it is listed at 58.46 (target range: 56 - 61), showing a change of -1.21 (-2.02782%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Morepen Laboratories Limited Graph
Morepen Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Morepen Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 58.45, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 58.46 | 59.04 | 53.14 - 64.95 |
59.63 | 47.70 - 71.56 | ||
60.21 | 42.15 - 78.28 | ||
Bearish Scenario | 58.46 | 57.88 | 52.09 - 63.66 |
57.29 | 45.83 - 68.75 | ||
56.71 | 39.69 - 73.72 |
Overview of Morepen Laboratories Limited
ISIN
INE083A01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
4,669,231
Market Cap
34,045,825,863
Last Dividend
0
Official Website
IPO Date
1996-01-01
DCF Diff
115.48
DCF
-56
Financial Ratios Every Investor Needs
Stock Dividend of MOREPENLAB
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2002-09-18 | September 18, 02 | 0.6 | 0.6 | 2002-09-23 | 2002-10-08 | 2002-07-01 |
2001-09-03 | September 03, 01 | 0.2 | 0.2 | 2001-09-16 | 2001-10-01 | 2001-06-16 |
2001-01-24 | January 24, 01 | 0.5 | 0.5 | 2001-02-09 | 2001-03-01 | 2001-01-16 |
2000-08-18 | August 18, 00 | 0.1 | 0.5 | 2000-09-04 | 2000-10-01 | 2000-07-18 |
2000-04-28 | April 28, 00 | 0.6 | 3 | 2000-05-15 | 2000-06-01 | 2000-04-18 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1,829.94 Cr | 1,199.93 Cr | 630.01 Cr | 0.3443 | 0.00 Cr | 234.18 Cr | 315.85 Cr | 118.02 Cr | 2.20 | 192.43 Cr | 0.0645 |
2024-03-31 | 1,701.90 Cr | 1,083.52 Cr | 618.38 Cr | 0.3633 | 5.20 Cr | 83.57 Cr | 417.38 Cr | 96.16 Cr | 1.88 | 172.60 Cr | 0.0565 |
2023-03-31 | 1,417.53 Cr | 955.74 Cr | 461.79 Cr | 0.3258 | 3.07 Cr | 14.16 Cr | 56.08 Cr | 38.68 Cr | 0.77 | 85.67 Cr | 0.0273 |
2022-03-31 | 1,541.57 Cr | 1,060.94 Cr | 480.63 Cr | 0.3118 | 3.01 Cr | 14.19 Cr | 118.01 Cr | 101.68 Cr | 2.26 | 156.77 Cr | 0.0660 |
2021-03-31 | 1,175.37 Cr | 786.78 Cr | 388.59 Cr | 0.3306 | 5.65 Cr | 12.17 Cr | 98.17 Cr | 97.09 Cr | 2.16 | 128.45 Cr | 0.0826 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 49.36 Cr | 1,778.10 Cr | 591.14 Cr | 1,156.2307 Cr | 105.10 Cr | 55.73 Cr | 299.97 Cr | 370.33 Cr | 0.00 Cr | 0.00 Cr | 7.17 Cr | 500.6536 Cr |
2024-03-31 | 16.95 Cr | 1,293.21 Cr | 445.98 Cr | 847.2262 Cr | 29.00 Cr | 12.05 Cr | 248.59 Cr | 301.30 Cr | 1.54 Cr | 0.00 Cr | 0.00 Cr | 402.0446 Cr |
2023-03-31 | 21.67 Cr | 1,110.50 Cr | 358.05 Cr | 752.9081 Cr | 25.16 Cr | 3.50 Cr | 228.89 Cr | 184.01 Cr | 66.37 Cr | 34.20 Cr | -33.77 Cr | 321.1631 Cr |
2022-03-31 | 15.80 Cr | 1,070.05 Cr | 491.95 Cr | 578.5612 Cr | 18.57 Cr | 2.77 Cr | 275.85 Cr | 160.79 Cr | 180.51 Cr | 33.01 Cr | 0.06 Cr | 456.4569 Cr |
2021-03-31 | 41.39 Cr | 858.15 Cr | 433.86 Cr | 424.7498 Cr | 17.05 Cr | -24.34 Cr | 175.33 Cr | 131.24 Cr | 178.15 Cr | 0.00 Cr | 1.09 Cr | 403.8000 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 32.0567 Cr | -321.5066 Cr | 299.8860 Cr | -91.9764 Cr | 10.4361 Cr | 27.3812 Cr | -124.0331 Cr | 118.0204 Cr | 48.0966 Cr | 0.0000 Cr | -51.3708 Cr |
2024-03-31 | 73.3746 Cr | -83.3002 Cr | 5.2049 Cr | -7.9609 Cr | -4.7207 Cr | 16.9451 Cr | -71.3808 Cr | 96.1599 Cr | 3.8351 Cr | 0.0000 Cr | -19.7079 Cr |
2023-03-31 | -91.1706 Cr | -46.5093 Cr | 143.5431 Cr | -137.1426 Cr | 5.8632 Cr | 21.6658 Cr | -45.9720 Cr | 55.7553 Cr | 6.5951 Cr | 0.0000 Cr | 46.9678 Cr |
2022-03-31 | -57.7576 Cr | -31.6785 Cr | 63.8518 Cr | -125.1256 Cr | -25.5843 Cr | 15.8026 Cr | -67.3680 Cr | 126.7026 Cr | 1.5233 Cr | 0.0000 Cr | -100.5287 Cr |
2021-03-31 | 50.8257 Cr | -70.3507 Cr | 47.2728 Cr | 10.4273 Cr | 27.7478 Cr | 41.3869 Cr | -40.3984 Cr | 98.5115 Cr | 3.5776 Cr | -0.4892 Cr | -36.8500 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 470.46 Cr | 327.82 Cr | 142.65 Cr | 0.3032 | 73.15 Cr | 20.32 Cr | 0.35 | 37.63 Cr | 0.0432 |
2024-12-31 | 452.78 Cr | 290.65 Cr | 162.13 Cr | 0.3581 | 31.21 Cr | 26.69 Cr | 0.49 | 41.48 Cr | 0.0589 |
2024-09-30 | 437.73 Cr | 270.10 Cr | 167.63 Cr | 0.3830 | 42.21 Cr | 34.85 Cr | 0.65 | 49.06 Cr | 0.0796 |
2024-06-30 | 455.22 Cr | 345.77 Cr | 109.45 Cr | 0.2404 | 15.05 Cr | 36.17 Cr | 0.71 | 55.05 Cr | 0.0795 |
2024-03-31 | 360.11 Cr | 255.04 Cr | 105.07 Cr | 0.2918 | 8.58 Cr | 8.24 Cr | 0.17 | 52.62 Cr | 0.0229 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 49.36 Cr | 77.81 Cr | 127.17 Cr | 324.76 Cr | 299.97 Cr | 1,159.37 Cr | 370.33 Cr | 1,778.10 Cr | 591.14 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 186.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,110.43 Cr |
2024-09-30 | 19.55 Cr | 184.67 Cr | 204.22 Cr | 0.00 Cr | 282.39 Cr | 1,092.98 Cr | 269.83 Cr | 1,562.25 Cr | 451.82 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | -847.23 Cr |
2024-03-31 | 52.12 Cr | 49.55 Cr | 52.12 Cr | 324.94 Cr | 248.59 Cr | 889.04 Cr | 237.66 Cr | 1,293.21 Cr | 445.98 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 20.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 26.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 34.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 36.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 28.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2000-11-07 | November 07, 00 | 5:1 |
1996-09-09 | September 09, 96 | 47:40 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,706.70 | ₹4,094,851,176,000.00 | ₹3,230,078.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,595.50 | ₹1,750,900,789,500.00 | ₹208,221.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,741.90 | ₹1,266,427,345,500.00 | ₹261,642.00 |
Mankind Pharma Limited | MANKIND | ₹2,567.20 | ₹1,059,557,272,672.00 | ₹454,636.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,270.30 | ₹1,057,311,434,873.00 | ₹1,968,798.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹969.80 | ₹975,841,854,000.00 | ₹1,184,140.00 |
Lupin Limited | LUPIN | ₹1,929.10 | ₹881,110,637,700.00 | ₹1,105,279.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,137.80 | ₹660,836,515,600.00 | ₹5,489,663.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,134.10 | ₹602,245,154,100.00 | ₹992,818.00 |
Alkem Laboratories Limited | ALKEM | ₹5,031.10 | ₹601,543,471,500.00 | ₹118,281.00 |
Laurus Labs Limited | LAURUSLABS | ₹874.35 | ₹471,772,155,150.00 | ₹3,032,532.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Cohance Lifesciences Limited | COHANCE | ₹998.45 | ₹381,974,029,138.00 | ₹410,439.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,473.90 | ₹373,934,325,600.00 | ₹302,398.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,751.40 | ₹343,682,876,800.00 | ₹77,148.00 |
Piramal Enterprises Limited | PEL | ₹1,251.80 | ₹283,755,520,400.00 | ₹2,308,743.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,769.30 | ₹276,573,437,400.00 | ₹284,299.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,667.50 | ₹270,933,732,500.00 | ₹282,417.00 |
Eris Lifesciences Limited | ERIS | ₹1,798.90 | ₹245,004,783,300.00 | ₹52,393.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,186.00 | ₹229,650,000,000.00 | ₹15,858.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹977.90 | ₹192,218,957,700.00 | ₹54,884.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,194.10 | ₹190,197,442,100.00 | ₹370,820.00 |
NATCO Pharma Limited | NATCOPHARM | ₹953.40 | ₹170,763,474,000.00 | ₹430,795.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,281.00 | ₹170,393,901,900.00 | ₹72,413.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,066.40 | ₹157,070,576,880.00 | ₹60,750.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹474.90 | ₹115,231,635,600.00 | ₹940,401.00 |
Procter & Gamble Health Limited | PGHL | ₹5,918.50 | ₹98,243,548,900.00 | ₹6,998.00 |
Shilpa Medicare Limited | SHILPAMED | ₹888.25 | ₹86,862,766,925.00 | ₹105,636.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹911.20 | ₹82,586,265,744.00 | ₹287,584.00 |
Strides Pharma Science Limited | STAR | ₹874.10 | ₹80,559,416,070.00 | ₹774,363.00 |
FDC Limited | FDC | ₹479.35 | ₹78,042,973,500.00 | ₹94,963.00 |
Suven Life Sciences Limited | SUVEN | ₹272.37 | ₹59,396,815,380.00 | ₹127,697.00 |
Innova Captab Limited | INNOVACAP | ₹909.35 | ₹52,037,490,096.00 | ₹29,685.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹150.54 | ₹48,853,541,880.00 | ₹152,010.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹506.75 | ₹46,251,072,500.00 | ₹306,148.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹623.45 | ₹43,894,496,010.00 | ₹55,475.00 |
Sequent Scientific Limited | SEQUENT | ₹171.97 | ₹43,050,109,950.00 | ₹363,036.00 |
Hikal Limited | HIKAL | ₹323.10 | ₹39,838,553,100.00 | ₹170,616.00 |
Gufic Biosciences Limited | GUFICBIO | ₹397.10 | ₹39,820,393,800.00 | ₹123,432.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,401.00 | ₹39,710,139,000.00 | ₹24,441.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹740.40 | ₹37,552,421,640.00 | ₹56,665.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹58.45 | ₹32,027,911,300.00 | ₹1,497,181.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹641.85 | ₹30,907,003,050.00 | ₹88,498.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹103.16 | ₹30,280,245,320.00 | ₹5,353,453.00 |
Indoco Remedies Limited | INDOCO | ₹317.85 | ₹29,320,995,015.00 | ₹63,895.00 |
Alembic Limited | ALEMBICLTD | ₹112.12 | ₹28,790,397,728.00 | ₹257,904.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1985
Gender: male
Year Born: 1987
Gender: male
Year Born: 1989
Gender: female
Year Born: 1966
Gender: male
Year Born:
Gender: female
Year Born: 1994
Gender: male
Year Born: 1964
Gender: male
Year Born: 1968
Gender: male
Year Born: 1967
FAQs about Morepen Laboratories Limited
The CEO is Sushil Suri FCA.
The current price is ₹59.79.
The range is ₹42-100.9.
The market capitalization is ₹3,404.58 crores.
The P/E ratio is 29.41.
The company operates in the Healthcare sector.
Overview of Morepen Laboratories Limited (ISIN: INE083A01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,404.58 crores and an average daily volume of 4,669,231 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.